Structure:action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat
- PMID: 2898902
Structure:action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat
Abstract
The hypothesis that the neuromuscular blocking potency of pancuronium and vecuronium depends on the two acetylcholine moieties present at positions 3 and 17 was tested in cats by examining the neuromuscular profile of several desacetoxy analogues. Blockade of sciatic nerve-induced contraction of the tibialis and soleus muscles, as well as the effects on vagal-induced bradycardia and on sympathetically induced contractions of the nictitating membrane, were studied. The bis-desacetoxy analogue of pancuronium (ORG 7931) was one-fifth as potent as the parent compound as a neuromuscular blocking drug and as a vagolytic agent, but the neuromuscular block was faster in onset and shorter in duration than that produced by pancuronium. The desacetoxy analogues of vecuronium (ORG 8730 and ORG 8764) also were less potent neuromuscular blocking drugs, and, in addition, produced more vagal block than did vecuronium itself. The neuromuscular block produced by these desacetoxy analogues was of more rapid onset and shorter duration than that produced by vecuronium. The results thus showed that the greater neuromuscular blocking potency of pancuronium and vecuronium is lost after removal of one or both of the acetylcholine moieties. An analysis of the relationship between neuromuscular blocking dose and duration of action revealed that it was reciprocal, and it is suggested that a nondepolarizing equivalent of suxamethonium, when discovered, may necessarily be a drug of relatively low potency.
Similar articles
-
Dose-response relation, neuromuscular blocking action, intubation conditions, and cardiovascular effects of Org 9273, a new neuromuscular blocking agent.Anesth Analg. 1991 Jun;72(6):811-6. Anesth Analg. 1991. PMID: 1674648
-
Neuromuscular and vagal blocking actions of pancuronium bromide, its metabolites, and vecuronium bromide (Org NC45) and its potential metabolites in the anaesthetized cat.Br J Anaesth. 1983 Aug;55(8):703-14. doi: 10.1093/bja/55.8.703. Br J Anaesth. 1983. PMID: 6136285
-
Train-of-four fade and neuromuscular block in rats: a comparison between pancuronium, vecuronium, and rocuronium.Can J Anaesth. 2000 Oct;47(10):950-5. doi: 10.1007/BF03024864. Can J Anaesth. 2000. PMID: 11032268
-
Comparison of the pharmacology and vecuronium and atracurium with that of other currently available muscle relaxants.Anesth Analg. 1983 May;62(5):524-31. Anesth Analg. 1983. PMID: 6132564 Review. No abstract available.
-
[Clinicopharmacology of Arduan].Acta Pharm Hung. 1992 May;62(3):133-8. Acta Pharm Hung. 1992. PMID: 1354406 Review. Hungarian.
Cited by
-
Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use.Drugs. 1992 Aug;44(2):182-99. doi: 10.2165/00003495-199244020-00003. Drugs. 1992. PMID: 1382013 Review.
-
Factors that affect the onset of action of non-depolarizing neuromuscular blocking agents.Korean J Anesthesiol. 2017 Oct;70(5):500-510. doi: 10.4097/kjae.2017.70.5.500. Epub 2017 Sep 28. Korean J Anesthesiol. 2017. PMID: 29046769 Free PMC article. Review.
-
Effect of severe cardiac valve regurgitation on the onset of the neuromuscular blocking action of pancuronium.J Anesth. 1998 Mar;12(1):46-48. doi: 10.1007/BF02480767. J Anesth. 1998. PMID: 28921333 No abstract available.
-
Rocuronium (ORG 9426) neuromuscular blockade at the adductor muscles of the larynx and adductor pollicis in humans.Can J Anaesth. 1992 Sep;39(7):665-9. doi: 10.1007/BF03008227. Can J Anaesth. 1992. PMID: 1394754 Clinical Trial.
-
Nondepolarizing neuromuscular blocking drugs and train-of-four fade.Can J Anaesth. 1995 Mar;42(3):213-6. doi: 10.1007/BF03010679. Can J Anaesth. 1995. PMID: 7743572 Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous